Background Endocarditis and bacteraemia are devastating infections with high mortality.
Gram-positive cocci are the most commonly isolated pathogens. In an era of multidrug …

Study Objective. To evaluate the outcomes in patients with bacteremia and/or infective
endocarditis who were treated with daptomycin. Design. Retrospective chart review. Setting …

Background: Daptomycin is approved for the treatment of skin and skin-structure infections
(4 mg/kg) and Staphylococcus aureus bacteremia, including right-sided endocarditis (β …

Daptomycin, a cyclic lipopeptide with rapid bactericidal activity, is approved at doses of 4
mg/kg and 6 mg/kg for the treatment of its respective indications [ie complicated skin and soft …

Assessment of the place of daptomycin in the treatment of endocarditis and bacteraemia
requires assimilation of data from one open-label randomized comparative clinical trial sized …

With a decreasing pipeline of novel antibiotics and increasing antibacterial resistance, the
need to optimise the current antibiotics in our armamentarium has become vitally important …

Objectives Infective endocarditis (IE) is a complex infection associated with high mortality.
Daptomycin, a cyclic lipopeptide antibiotic highly active against Gram-positive bacteria, has …

Introduction Daptomycin, a rapid concentration-dependent bactericidal antibiotic, is
approved at a dose of 4 mg/kg/day for the treatment of complicated skin and soft tissue …

Infections caused by Gram-positive pathogens remain a major public health burden and are
associated with high morbidity and mortality. Increasing rates of infection with Gram-positive …

Daptomycin is commonly used at doses> 6 mg/kg/day for various indications, including
infective endocarditis (IE). A systematic assessment of skeletal muscle, renal …